Cardinal Health Builds On Generic Device Strategy With Cordis Deal
This article was originally published in The Gray Sheet
Executive Summary
The $1.99 billion Cordis acquisition is a major step in Cardinal's strategy to build its offerings of devices with a high physician preference but for which there is limited clinical differentiation and inefficient supply chains.
You may also be interested in...
Device Firm Earnings: Winners And Losers
In this earnings review, we pick out the high achievers and underperformers from the companies that released quarterly results in the past week. Reports from J&J, ResMed, bioMérieux, St. Jude Medical and more.
Vascular Closure Market Makes Room For Innovative Solutions
The $1 billion vascular closure market is primed for growth. It comes on the back of intensive R&D that has spawned a range of alternatives to the traditional manual/compression approach, giving SJM and the sector’s other heavyweights cause to look over their shoulders.
Device/Diagnostics Quarterly Deal Statistics, Q1 2015
Device financing rose slightly to $934 million in Q1, while acquisition value was down to just over $4 billion. Diagnostics fundraising dropped significantly to $597 million; M&A activity was dominated by NGS and Roche's transaction with Foundation Medicine.